MUC16 and prostate carcinoma: Indeed, some of the most common clinically used biomarkers for cancer diagnosis and monitoring are glycoproteins, and are known to be aberrantly glycosylated in cancer (e.g., PSA for prostate cancer; MUC16 for ovarian cancer; and SLea for pancreatic cancer) [204].